Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing

Boxer Capital Management, LLC reported a bargain of 386,000 Kodiak Sciences (NASDAQ:KOD) shares successful its February 17, 2026, SEC filing, an estimated $7.90 cardinal commercialized based connected quarterly mean pricing.

In a February 17, 2026, SEC filing, Boxer Capital Management, LLC disclosed the acquisition of 386,000 further shares of Kodiak Sciences. The estimated transaction worth was $7.90 million, based connected the mean unadjusted closing terms implicit the October to December 2025 quarter. The Kodiak Sciences position’s worth accrued by $19.49 cardinal since the erstwhile filing, a fig that reflects some caller stock purchases and stock terms appreciation.

The bargain brought Kodiak Sciences to 6.95% of Boxer Capital Management, LLC’s 13F reportable AUM.

Top 5 holdings aft the filing:

• NASDAQ:TNGX: $96.36 cardinal (21.1% of AUM)

• NASDAQ:RVMD: $31.86 cardinal (7.0% of AUM)

• NASDAQ: KOD: $31.76 cardinal (7.0% of AUM)

• NASDAQ:KYMR: $25.61 cardinal (5.6% of AUM)

• NASDAQ:CELC: $22.44 cardinal (4.9% of AUM)

As of February 17, 2026, Kodiak Sciences shares were priced astatine $22.66, up 340.0% implicit the past year, outperforming the S&P 500 by 318.88 percent points.

• Develops and advances therapeutics for retinal diseases, with pb campaigner KSI-301 successful Phase IIb/III objective trials targeting bedewed age-related macular degeneration and different retinal indications.

• Operates a clinical-stage biopharmaceutical model, generating gross chiefly done the aboriginal commercialization of proprietary cause candidates presently successful development.

• Develops therapeutics for retinal diseases, including age-related macular degeneration and diabetic macular edema.

Kodiak Sciences is simply a clinical-stage biotechnology institution specializing successful the probe and improvement of caller therapies for retinal diseases. The company's strategy centers connected leveraging its antibody biopolymer conjugate level to code important unmet needs successful ophthalmology. With a focused pipeline and a pb campaigner successful late-stage trials, Kodiak Sciences aims to found a competitory borderline done innovative subject and targeted marketplace positioning.

Boxer Capital, a California-based concern firm, precocious disclosed the acquisition of astir $7.9 cardinal worthy of Kodiak Sciences stock. Here are immoderate cardinal takeaways for mean investors.

First off, Kodiak banal has performed exceptionally good implicit the past year. During that time, shares are up an astounding 564%. Therefore, it’s nary astonishment that a biotech-focused steadfast similar Boxer Capital has added aggressively to its presumption successful the company. Kodiak present represents the firm’s third-largest presumption by plus value, comprising astir 7% of the firms wide AUM.